Heterogenous antigens in vaccine preparations ofVibrio cholerae

Zhukov-Verezhnikov, N. N.; Anisimov, P. I.; Гончарова, Н. С.; Bochko, G. M.; Karaseva, Z. N.; Shanina, L. N.; Fomin, S. N.

doi:10.1007/bf00785556

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second approach, pathogenic bacteria are isolated from infections and tested against a large, generally well-characterized collection of previously isolated phages. Some studies from Russia, e.g., Zhukov-Verezhnikov et al 98 showed that the resulting custom-designed phage preparations often worked better than mainstream-production phage preparations. This is also the approach generally used in Poland.…”

Section: Phages As Antibacterial "Drugs"mentioning

confidence: 98%

Phage treatment of human infections

et al. 2011

View full text Add to dashboard Cite

Phages as bactericidal agents have been employed for 90 years as a means of treating bacterial infections in humans as well as other species, a process known as phage therapy. In this review we explore both the early historical and more modern use of phages to treat human infections. We discuss in particular the little-reviewed French early work, along with the Polish, US, Georgian and Russian historical experiences. We also cover other, more modern examples of phage therapy of humans as differentiated in terms of disease. In addition, we provide discussions of phage safety, other aspects of phage therapy pharmacology, and the idea of phage use as probiotics.

show abstract

Section: Phages As Antibacterial "Drugs"mentioning

confidence: 98%

Phage treatment of human infections

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Phage therapy has distinct advantages over conventional antibiotic treatment in that phages are (i) a naturally occurring antibacterial, (ii) self-replicating, (iii) self-limiting upon resolution of infection, (iv) effective against both MDR or antibiotic sensitive bacteria, (v) highly specific with low inherent toxicity, (vi) able to co-evolve with bacteria, and (vii) able to penetrate biofilms (5). The potential use of phages as antibacterial agents has been demonstrated in in vitro (6,7), preclinical (8)(9)(10)(11) and in compassionate single case studies (12)(13)(14).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics and pharmacodynamics of inhaled antipseudomonal bacteriophage therapy in mice

Chow

Chang

et al. 2020

Preprint

View full text Add to dashboard Cite

Inhaled bacteriophage (phage) therapy is a potential alternative to conventional antibiotic therapy to combat multidrug-resistant (MDR) Pseudomonas aeruginosa infections. However, pharmacokinetics (PK) and pharmacodynamics (PD) of phages are fundamentally different to antibiotics and the lack of understanding potentially limits optimal dosing. The aim of this study was to investigate the in vivo PK and PD profiles of antipseudomonal phage PEV31 delivered by pulmonary route in mice. BALB/c mice were administered phage PEV31 at doses of 107 and 109 PFU by the intratracheal route. Mice (n = 4) were sacrificed at 0, 1, 2, 4, 8 and 24 h post-treatment and various tissues (lungs, kidney, spleen and liver), bronchoalveolar lavage and blood were collected for phage quantification. In a separate study, mice (n = 4) were treated with PEV31 (109 PFU) or PBS at 2 h post-inoculation with MDR P. aeruginosa. Infective PEV31 and bacteria were enumerated from the lungs. In the phage only study, PEV31 titer gradually decreased in the lungs over 24 hours with a half-life of approximately 8 h for both doses. In the presence of bacteria, PEV31 titer increased by almost 2-log10 in the lungs at 16 h. Furthermore, bacterial growth was suppressed in the PEV31-treated group, while the PBS-treated group showed exponential growth. Some phage-resistant colonies were observed from the lung homogenates sampled at 24 h post-phage treatment. These colonies had a different antibiogram to the parent bacteria. This study provides evidence that pulmonary delivery of phage PEV31 in mice can reduce the MDR bacterial burden.

show abstract

Heterogenous antigens in vaccine preparations ofVibrio cholerae

Cited by 2 publications

References 0 publications

Phage treatment of human infections

Phage treatment of human infections

Pharmacokinetics and pharmacodynamics of inhaled antipseudomonal bacteriophage therapy in mice

Contact Info

Product

Resources

About